 |
 |
醫(yī)學(xué)論文范文:復(fù)灌時(shí)參附注射液處理可減輕大鼠心肌缺血/再灌注損傷
【摘要】 目的 觀察復(fù)灌時(shí)參附注射液處理對(duì)大鼠心肌缺血/再灌注損傷的影響。方法 利用大鼠Langendorff離體心臟灌流模型，制備心肌缺血再灌注損傷模型，在心臟缺血后再灌注同時(shí)給予參附注射液，觀察大鼠心臟左室舒張末壓(LVEDP)、左室發(fā)展壓(LVDP)、左室內(nèi)壓最大變化速率(±dp/dtmax)和心率(HR),以及心肌組織中的ATP含量、丙二醛(MDA)含量、超氧化物歧化酶(SOD)活性、冠脈流出液中肌酸激酶(CK)含量的變化。實(shí)驗(yàn)分為4組：正常對(duì)照組、單純?nèi)毖?再灌注組、參附注射液30 ml/L組和60 ml/L組。結(jié)果 缺血/再灌注組大鼠心肌ATP含量和SOD活性明顯降低，MDA和CK含量明顯升高。與缺血/再灌注組比較，參附注射液60 ml/L組心肌MDA值減少，SOD值升高，ATP含量增加，冠脈流出液CK含量減少;血流動(dòng)力學(xué)指標(biāo)明顯改善。結(jié)論 復(fù)灌時(shí)參附注射液處理可提高心肌組織ATP含量和SOD活性，減少M(fèi)DA生成，減少CK含量，保護(hù)缺血/再灌注后的大鼠心臟。
【關(guān)鍵詞】 參附注射液;心肌;缺血再灌注
Simultaneous Shenfu injection treatment during reperfusion mitigates ischemia/reperfusion myocardium injury in isolated rat hearts
XU Pengcheng, FENG Haorong, DAI Tijun
1. Jiangsu Provincial Key Laboratory of Anesthesiology, Xuzhou, Jiangsu 221002, China; 2. Department of Anesthesiology, 98th Hospital of PLA, Huzhou, Zhejiang 313000;3. Department of Anesthetic Pharmacology, Xuzhou Medical College, Xuzhou, Jiangsu 221004醫(yī)學(xué) 全在.線提供m.f1411.cn
Abstract: Objective To investigate the effect of simultaneous treatment with Shenfu injection (SF) during reperfusion on myocardial ischemia/reperfusion injury in rats. Methods The myocardial ischemia/reperfusion model was prepared based on the Langendorff model for the perfusion of isolated rat heart. Following ischemia, reperfusion was allowed with SF injection administered simultaneously. The hemodynamic variables, such as left ventricular end-diastolic pressure (LVEDP), left ventricular developed pressure (LVDP), rate of left ventricular pressure development/relaxation (±dp/dtmax) and heart rate (HR), and the content of adenosine triphosphate (ATP), malendialdehyde (MDA), superoxide dismutase (SOD) in myocardial tissue and the activities of creatine kinase (CK) in coronary effluent fluid were observed. The isolated perfused rat hearts were separated into control, ischemia/reperfusion, SF 30 ml/L and SF 60 ml/L groups. Results In the ischemia/reperfusion group, the content of ATP and activity of SOD significantly decreased; the activities of MDA and CK significantly increased. SF 60 ml/L attenuated the decrease of SOD and the increase of MDA and CK compared with the ischemia/reperfusion group. SF 60 ml/L significantly improved the recovery of the hemodynamic variables and myocardial ATP concentrations following ischemia and reperfusion. Conclusion Simultaneous SF treatment during reperfusion could provide the cardiac protection effect against the ischemia/reperfusion injury by increasing the content of ATP and activity of SOD and decreasing the activity of MDA and CK in myocardial.
Key words: Shenfu injection; myocardium; ischemia/reperfusion
參附注射液是一種中藥針劑,由紅參和黑附片提取物組成, 主要有效成分為人參皂苷和烏頭堿,目前臨床已廣泛用來治療心絞痛、心肌梗死、心力衰竭等疾患，也被用于體外循環(huán)心臟瓣膜置換術(shù)[1-3]。近年來，實(shí)驗(yàn)已證實(shí)在缺血前應(yīng)用參附注射液對(duì)缺血/ 再灌注損傷心肌有保護(hù)作用[4-5]。但復(fù)灌時(shí)應(yīng)用參附注射液對(duì)心肌缺血/再灌注損傷的作用如何尚不十分清楚，本實(shí)驗(yàn)采用Langendorff 大鼠離體心臟灌流模型, 觀察復(fù)灌后應(yīng)用參附注射液對(duì)離體大鼠心臟缺血/再灌注后血流動(dòng)力學(xué)以及組織中的高能磷酸化合物ATP含量的影響，為臨床治療用藥提供實(shí)驗(yàn)基礎(chǔ)。
